Oct 30, 2018 · Protein tyrosine phosphatase SHP2 functions as a key regulator of cell cycle control, and activating mutations cause several cancers. Here, we dissect the energy …

Juvenile myelomonocytic leukemia (JMML), an invasive myeloproliferative neoplasm, is a childhood disease with very high clinical lethality. Somatic mutation E76K in SHP2 is the most …

Moreover, puncta formation of both SHP2 D61G in Ptpn11 D61G/+ MEFs and SHP2 E76K in Ptpn11 E76K/+ MSCs was strongly abolished by the treatment of ET070 (Figures S4F and S4G).

In vitro, SHP2 E76K and SHP2 WT promoted malignant biological behaviors of CRC cells and induced epithelial-mesenchymal transition (EMT) via the Wnt/β-catenin signaling pathway. …

The aim of this study was to investigate the effects of gain-of-function (GOF) E76K-mutant Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) on the biological …

Oct 30, 2018 · We report an open-state structure of a SHP2 variant that bears a potent activating mutation, E76K, which induces a dramatic domain reorganization to expose the active site and …

Nov 14, 2016 · Here we show that the interaction between leukemia-associated mutant Shp2 and Gab2, a scaffolding protein important for cytokine-induced PI3K/Akt signaling, was enhanced, …

Gain-of-function Shp2 mutants such as Shp2 E76K are associated with myeloid leukemias. We found that Shp2 E76K could transform cytokine-dependent human TF-1 myeloid cells into …

Aug 20, 2018 · Juvenile myelomonocytic leukemia (JMML), an invasive myeloproliferative neoplasm, is a childhood disease with very high clinical lethality. Somatic mutation E76K in …

Oct 10, 2020 · Disease-associated mutants of a critical phosphatase in the RAS-MAPK pathway undergo phase separation through a dominant gain-of-function mechanism, explaining how …